Versant Venture Management LLC maintained its stake in shares of Second Sight Medical Products, Inc. (NASDAQ:EYES) during the second quarter, Holdings Channel reports. The fund owned 4,492,975 shares of the medical device company’s stock at the end of the second quarter. Second Sight Medical Products accounts for 4.4% of Versant Venture Management LLC’s portfolio, making the stock its 7th largest position. Versant Venture Management LLC owned 0.08% of Second Sight Medical Products worth $5,616,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. BNP Paribas Arbitrage SA raised its stake in shares of Second Sight Medical Products by 980,566.2% in the first quarter. BNP Paribas Arbitrage SA now owns 696,273 shares of the medical device company’s stock valued at $258,000 after buying an additional 696,202 shares in the last quarter. Van Den Berg Management I Inc. raised its stake in shares of Second Sight Medical Products by 27.2% in the first quarter. Van Den Berg Management I Inc. now owns 243,679 shares of the medical device company’s stock valued at $295,000 after buying an additional 52,102 shares in the last quarter. Finally, Carl Domino Inc raised its stake in shares of Second Sight Medical Products by 27.5% in the first quarter. Carl Domino Inc now owns 112,719 shares of the medical device company’s stock valued at $136,000 after buying an additional 24,308 shares in the last quarter. Hedge funds and other institutional investors own 15.58% of the company’s stock.

Shares of Second Sight Medical Products, Inc. (EYES) opened at 0.9641 on Friday. Second Sight Medical Products, Inc. has a one year low of $0.90 and a one year high of $3.92. The firm’s market capitalization is $54.48 million. The stock’s 50 day moving average price is $1.24 and its 200 day moving average price is $1.31.

Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.01. The business had revenue of $2.24 million during the quarter, compared to the consensus estimate of $1.43 million. Second Sight Medical Products had a negative return on equity of 168.49% and a negative net margin of 646.89%. Second Sight Medical Products’s quarterly revenue was up 124.0% on a year-over-year basis. During the same period last year, the company earned ($0.17) earnings per share. Analysts expect that Second Sight Medical Products, Inc. will post ($0.55) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Second Sight Medical Products, Inc. (NASDAQ:EYES) Position Held by Versant Venture Management LLC” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/second-sight-medical-products-inc-nasdaqeyes-position-held-by-versant-venture-management-llc/1478764.html.

EYES has been the subject of several research reports. HC Wainwright set a $5.00 price target on Second Sight Medical Products and gave the company a “buy” rating in a report on Tuesday. Zacks Investment Research lowered Second Sight Medical Products from a “hold” rating to a “sell” rating in a report on Thursday.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Want to see what other hedge funds are holding EYES? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Second Sight Medical Products, Inc. (NASDAQ:EYES).

Institutional Ownership by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.